← Leaderboards
Chloe L Thio
Johns Hopkins University
$13,807,555
Attributed
$18,642,206
Total exposure
30
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,146,476 · 31
By mechanism
R01$13,423,067 · 6
U19$7,424,537 · 17
R56$1,117,438 · 2
R21$1,105,314 · 3
K08$634,267 · 1
R03$441,853 · 2
Top collaborators
- Ashwin Balagopal11 shared
- Andrea L Cox5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Kathleen Schwarz$11,772,700
- David L Thomas$44,227,388
- Gregory D Kirk$60,349,977
- Priya Duggal$4,703,374
- Ann Carroll Klassen$1,639,492
Others in their field
Top investigators on “Persons”
- Wafaa M. El-Sadr · Columbia University Health Sciences$688,439,560
- Lawrence Corey · Fred Hutchinson Cancer Center$646,462,796
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- David R. Weir · University Of Michigan At Ann Arbor$386,183,647
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$377,922,183
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$265,384,316
Research focus
PersonsHepatitis B VirusViralLiverAffectChronic Hepatitis BVirus ReplicationHepatitis B Surface AntigensSamplingHepatitis BGenetic TranscriptionLiver DiseasesViral DnaCohortTissuesInfectionBloodResearch PersonnelGenomeVirusHepatitis B E AntigensPlasmaVisitPrimary Carcinoma Of The Liver Cells
Grant awards (61)
Hepatitis B and HIV Cure Consortium (BICC)$4,640,294
U19 · FY2025 · AI · contact PI
HBV cccDNA transcriptional silencing with and without HIV$818,465
R01 · FY2025 · AI
Administrative Core$777,219
U19 · FY2025 · AI · contact PI
Virology Core$279,072
U19 · FY2025 · AI · contact PI
Hepatitis B and HIV Cure Consortium (BICC)$276,923
U19 · FY2025 · AI · contact PI
Hepatitis B and HIV Cure Consortium (BICC)$248,538
U19 · FY2025 · AI · contact PI
Shared Resources Core$223,868
U19 · FY2025 · AI · contact PI
Hepatitis B and HIV Cure Consortium (BICC)$184,960
U19 · FY2025 · AI · contact PI
Shared Resources Core$180,852
U19 · FY2025 · AI · contact PI
Hepatitis B and HIV Cure Consortium (BICC)$153,555
U19 · FY2025 · AI · contact PI
Shared Resources Core$146,851
U19 · FY2025 · AI · contact PI
Shared Resources Core$126,547
U19 · FY2025 · AI · contact PI
Virology Core$45,915
U19 · FY2025 · AI · contact PI
Virology Core$33,615
U19 · FY2025 · AI · contact PI
Clinical Project$21,771
U19 · FY2025 · AI · contact PI
Virology Core$20,224
U19 · FY2025 · AI · contact PI
Virology Core$20,190
U19 · FY2025 · AI · contact PI
Clinical Project$19,440
U19 · FY2025 · AI · contact PI
Clinical Project$12,701
U19 · FY2025 · AI · contact PI
Immune response dynamics and hepatitis B cure in persons with and without HIV infection$5,184
U19 · FY2025 · AI · contact PI
Immune response dynamics and hepatitis B cure in persons with and without HIV infection$4,627
U19 · FY2025 · AI · contact PI
Clinical Project$2,191
U19 · FY2025 · AI · contact PI
HBV cccDNA transcriptional silencing with and without HIV$730,270
R01 · FY2024 · AI
Mechanisms of HBV cccDNA transcriptional regulation in persons with and without HIV$810,981
R56 · FY2023 · AI
Identifying the source of hepatitis B surface antigen in people with hepatitis B-HIV co-infection$204,688
R21 · FY2022 · AI
Unraveling sources of hepatitis B surface antigen before and after nucleos(t)ide analogue treatment in People with HIV$204,688
R21 · FY2022 · AI
Characterization of silently HBV-infected hepatocytes in HIV co-infection$779,416
R01 · FY2021 · AI
Unraveling sources of hepatitis B surface antigen before and after nucleos(t)ide analogue treatment in People with HIV$245,625
R21 · FY2021 · AI
Identifying the source of hepatitis B surface antigen in people with hepatitis B-HIV co-infection$245,625
R21 · FY2021 · AI
Characterization of silently HBV-infected hepatocytes in HIV co-infection$790,878
R01 · FY2020 · AI
Characterization of silently HBV-infected hepatocytes in HIV co-infection$799,884
R01 · FY2019 · AI
Immune correlates of acute HBV recovery with and without HIV$611,631
R01 · FY2019 · AI · contact PI
Characterization of silently HBV-infected hepatocytes in HIV co-infection$790,717
R01 · FY2018 · AI
Immune correlates of acute HBV recovery with and without HIV$616,491
R01 · FY2018 · AI · contact PI
Immune correlates of HAART-mediated spontaneous control of chronic HCV infection$204,688
R21 · FY2018 · AI · contact PI
Immune correlates of acute HBV recovery with and without HIV$649,053
R01 · FY2017 · AI · contact PI
Immune correlates of acute HBV recovery with and without HIV$666,387
R01 · FY2016 · AI · contact PI
Immune correlates of acute HBV recovery with and without HIV$704,503
R01 · FY2015 · AI · contact PI
HBV Response to Tenofovir or Lamivudine-Based ART in HIV-HBV Co-Infected Chinese$192,498
R01 · FY2015 · AI · contact PI
HBV Response to Tenofovir or Lamivudine-Based ART in HIV-HBV Co-Infected Chinese$195,877
R01 · FY2014 · AI · contact PI
HBV Response to Tenofovir or Lamivudine-Based ART in HIV-HBV Co-Infected Chinese$199,999
R01 · FY2013 · AI · contact PI
Incident Hepatitis B in Men with or at Risk for HIV Infection$82,000
R03 · FY2012 · AI · contact PI
Incident Hepatitis B in Men with or at Risk for HIV Infection$82,000
R03 · FY2011 · AI · contact PI
Hepatitis B treatment and HIV Infection in resources limited settings$308,517
R01 · FY2010 · AI · contact PI
Liver Disease and HIV-HBV co-infection in the HAART era$306,457
R56 · FY2010 · AI · contact PI
Hepatitis B treatment and HIV Infection in resources limited settings$403,334
R01 · FY2009 · AI · contact PI
Liver Disease and Drug Use in the HAART Era$116,398
R03 · FY2009 · DA · contact PI
Liver Disease and HIV-HBV Coinfection in the HAART era$587,069
R01 · FY2008 · AI · contact PI
Hepatitis B treatment and HIV Infection in resources limited settings$392,200
R01 · FY2008 · AI · contact PI
Liver Disease and Drug Use in the HAART Era$161,455
R03 · FY2008 · DA · contact PI
Liver Disease and HIV-HBV Coinfection in the HAART era$657,655
R01 · FY2007 · AI · contact PI
Hepatitis B treatment and HIV Infection in resources limited settings$397,603
R01 · FY2007 · AI · contact PI
Liver Disease and HIV-HBV Coinfection in the HAART era$555,332
R01 · FY2006 · AI · contact PI
Hepatitis B treatment and HIV Infection in resources limited settings$394,374
R01 · FY2006 · AI · contact PI
Liver Disease and HIV-HBV Coinfection in the HAART era$585,502
R01 · FY2005 · AI
Liver Disease and HIV-HBV Coinfection in the HAART era$595,412
R01 · FY2004 · AI
HEPATITIS C CLEARANCE AND HOST GENETIC FACTORS$137,021
K08 · FY2004 · DA
HEPATITIS C CLEARANCE AND HOST GENETIC FACTORS$129,919
K08 · FY2003 · DA
HEPATITIS C CLEARANCE AND HOST GENETIC FACTORS$126,045
K08 · FY2002 · DA
HEPATITIS C CLEARANCE AND HOST GENETIC FACTORS$122,729
K08 · FY2001 · DA
HEPATITIS C CLEARANCE AND HOST GENETIC FACTORS$118,553
K08 · FY2000 · DA